Clinical trials: FLU
Influenza
A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults
This study is designed to test the immunogenicity and reactogenicity of the FluarixTM/Influsplit SSW® influenza vaccine containing the influenza strains recommended for the 2009-2010 season.
- Trial name
- NCT00920374
- Testing
- Fluarix™/Influsplit SSW®
- Where
- 5 sites in Germany
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Effect of Oseltamivir on Cognitive Function in Subjects With Influenza
This study has been designed to determine if subjects treated with oseltamivir in addition to standard of care treatment for influenza demonstrate a greater improvement in attention / working memory / processing speed / mood as…
- Trial name
- FOCUS (NCT01249833)
- Testing
- Oseltamivir
- Where
- 16 sites in Canada
- Volunteers
- 122 people
- Sponsor
- Trial Management Group Inc.
COVID-19 Prevention
A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults
The purpose of this study is to demonstrate the non-inferiority (NI) of the humoral immune response of the 4 influenza vaccine strains after concomitant administration of the Ad26.COV2.S vaccine and a seasonal quadrivalent…
- Trial name
- NCT05091307
- Testing
- Ad26.COV2.S, Influenza Vaccine
- Where
- 31 sites in United States, Belgium and 1 more
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Influenza
From Innovation to Solutions: Childhood Influenza Vaccination Planning
The purpose of this study is to increase childhood influenza vaccination rates using the FDA licensed influenza vaccines according to national guidelines in a randomized cluster trial in which primary care offices are randomized…
- Trial name
- NCT01664793
- Testing
- 4 Pillars Immunization Toolkit
- Where
- United States
- Volunteers
- 87,665 people, healthy volunteers welcome
- Sponsor
- University of Pittsburgh
Virus Diseases, RNA Virus Infections
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03739112
- Testing
- Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 12,794 people, healthy volunteers welcome
- Sponsor
- Medicago
Influenza, Healthy
Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age
This study is being conducted to compare the immunogenicity, safety, and viral shedding of a new A/H1N1 strain that will be incorporated into the FluMist quadrivalent formulation for the 2017-2018 influenza season with the…
- Trial name
- FluMist (NCT03143101)
- Testing
- FluMist trivalent (2015-2016), FluMist Quadrivalent (2015-2016), FluMist Quadrivalent (2017-2018)
- Where
- 12 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human
Relenza® Sentinel Site Monitoring Program in Japan
To collect background information of patients receiving a prescription for Relenza® and study risk factors etc. for adverse drug reactions collected through spontaneous reporting.
- Trial name
- SSMP (NCT01199744)
- Testing
- zanamivir
- Volunteers
- 1,575 people
- Sponsor
- GlaxoSmithKline
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Reverse Genetic H9N2 Influenza Vaccine Study in Adults
The purpose of the study is to identify the optimal dose level of a reverse genetic (RG) reassortant H9N2 pandemic influenza vaccine for further product development.
- Trial name
- NCT01320696
- Testing
- Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine
- Where
- 5 sites in United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza, Human
A Study About Modified RNA Vaccines Against Influenza in Healthy Adults
The purpose of this study is to learn if modified RNA (modRNA) vaccines for the prevention of influenza are: safe; and how these vaccines produce an immune response in generally healthy adults.
- Trial name
- NCT06436703
- Testing
- Influenza ModRNA Vaccine, Quadrivalent Influenza Vaccine (QIV)
- Where
- 32 sites in United States
- Volunteers
- 1,202 people, healthy volunteers welcome
- Sponsor
- Pfizer
Influenza, Human
Phase 3 Pivotal Trial of NanoFlu™ in Older Adults
A Phase 3, randomized, observer-blinded, active-controlled trial to evaluate the immunogenicity and safety of a recombinant quadrivalent nanoparticle influenza vaccine with Matrix-M1 adjuvant (NanoFlu) compared with a licensed…
- Trial name
- NCT04120194
- Testing
- NanoFlu, Fluzone Quadrivalent
- Where
- 19 sites in United States
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novavax
Influenza
Clinical Efficacy of Trivalent Live-Attenuated Influenza Vaccine (LAIV) Among Children in Senegal
This study will provide the Senegal Ministry of Health with data on the clinical efficacy of the Live-Attenuated Influenza Vaccine (LAIV). This data will inform future policy considerations for influenza vaccine.
- Trial name
- NCT01854632
- Testing
- SIIL Live Attenuated Influenza Vaccine
- Where
- Senegal
- Volunteers
- 1,761 people, healthy volunteers welcome
- Sponsor
- PATH
Influenza
Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza
The purpose of this study is: to assess the efficacy of Ergoferon in treatment of influenza; to assess the safety of Ergoferon in treatment of influenza; to compare the efficacy of Ergoferon and Oseltamivir for treatment of…
- Trial name
- NCT01850446
- Testing
- Ergoferon, Oseltamivir
- Where
- 7 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Materia Medica Holding
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Avian Influenza
A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
This Phase 3 study evaluates the safety, immunogenicity and lot-to lot consistency of 3 lots of aH5N1c vaccine for pandemic avian influenza, in approximately 2394 healthy adults ≥18 years of age receiving the vaccine and 797…
- Trial name
- NCT02839330
- Testing
- aH5N1c
- Where
- 26 sites in United States
- Volunteers
- 3,196 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza Strains
The study is to assess whether the virosomal influenza vaccine for season 2012/2013 fulfills the EMA requirements for re-registration of influenza vaccines.
- Trial name
- NCT01631071
- Testing
- Virosomal influenza vaccine
- Where
- Switzerland
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hematopoietic Stem Cell Transplant, Hematologic Malignancy
Influenza Vaccine Post Allogeneic Transplant
Study Design: This is a randomized, single center study to evaluate immune responses to the seasonal influenza vaccine in allogeneic hematopoietic stem cell transplant (HSCT) recipients who receive one vaccine or two vaccine…
- Trial name
- NCT01215981
- Testing
- Influenza vaccine
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Healthy
A Study to Describe Pediatric Influenza Vaccine Coverage
The purpose of this study is to describe flu vaccine coverage in children under 18 years of age and to examine correlations between in-office flu vaccine coverage and the use of various tactics to increase vaccine coverage.
- Trial name
- NCT00639418
- Testing
- Influenza vaccination
- Where
- 187 sites in United States
- Volunteers
- 147,494 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy, no Evidence of Disease
Cholecalciferol and Flu Vaccine in Treating Healthy Participants
This randomized clinical trial studies cholecalciferol and flu vaccine in treating healthy participants. Cholecalciferol may increase the immunologic response of flu vaccine in healthy participants.
- Trial name
- NCT01561989
- Testing
- cholecalciferol, questionnaire administration, trivalent influenza vaccine
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Roswell Park Cancer Institute
Influenza, Common Cold
A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies
The study is designed to investigate whether paracetamol from a hot remedy reaches the plasma faster than standard paracetamol tablets.
- Trial name
- NCT01332578
- Testing
- Paracetamol, Phenylephrine, Ascorbic Acid
- Where
- United Kingdom
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline